eribulin mesylate + carboplatin
Phase 2UNKNOWNDevelopment Stage
Estrogen Receptor-negative Breast Cancer
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Male Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-negative Breast Cancer
Aug 1, 2011 → Jun 1, 2021
About eribulin mesylate + carboplatin
eribulin mesylate + carboplatin is a phase 2 stage product being developed by Eisai for Estrogen Receptor-negative Breast Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT01372579. Target conditions include Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Male Breast Cancer.
What happened to similar drugs?
1 of 3 similar drugs in Estrogen Receptor-negative Breast Cancer were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01372579 | Phase 2 | UNKNOWN |
Competing Products
20 competing products in Estrogen Receptor-negative Breast Cancer